IP Verse

Neuroderm competitive analysis

Loading summary...

Latest patents of Neuroderm opposed by its competitors

Explore Neuroderm's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2432454
Mar 1, 2017Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors1

Latest publications and patents of Neuroderm New

Explore the latest publications and patents granted to Neuroderm, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Neuroderm

EP2640358
Jan 3, 2018Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For SameNo Opposition Filed Within Time Limit
EP2432454
Mar 1, 2017Compositions For Continuous Administration Of Dopa Decarboxylase InhibitorsOpposition Rejected

Latest PTAB cases involving Neuroderm

Discover the latest PTAB cases involving Neuroderm, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 24, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Neuroderm

PGR2022-00040May 12, 2022NEURODERMABBVIEFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Neuroderm with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
NEURODERM - 11 -
ABBVIE109 - 1
TEVA PHARMACEUTICALS20916 - 12